• CAR-NK-exosomes demonstrated strong in vitro tumor-killing activity in TNBC cells
• Over 90% of TNBC cells were killed within 10 hours of treatment by CAR-NK-exosomes
• Results validate INOVIQ's CAR-NK-exosome technology at Peter Mac, a leading cancer research institute

INOVIQ Limited (ASX: IIQ) announced positive results from in vitro validation studies of its CAR-NK-exosome therapeutic candidate at the Peter MacCallum Cancer Centre (Peter Mac). The study confirmed the potent anti-tumour activity of INOVIQ's proprietary CAR-NK-exosomes in Triple Negative Breast Cancer (TNBC) cells, an aggressive and difficult-to-treat cancer. The in vitro efficacy of INOVIQ's CAR-NK-exosomes, derived from human CAR-NK cells, was evaluated in cultured TNBC (Hs578T) cells. The results showed rapid and sustained tumour cell killing in vitro, with over 90% of TNBC cells eliminated within 10 hours of treatment. In contrast, control groups, including untreated cells and those treated with non-CAR-NK exosomes, showed minimal tumour cell death. These findings highlight the potent tumour-killing activity of INOVIQ's CAR-NK-exosomes to target and destroy solid tumours. Professor Phillip K Darcy, Co-leader of the Cancer Immunology program and Group Leader of the Cancer Immunotherapy Laboratory at the Peter Mac and an INOVIQ Medical and Scientific Advisory Board member, said the team successfully validated the in vitro tumour-killing activity of INOVIQ's CAR-NK-exosomes against TNBC cells and that CAR-exosomes represent a next-generation, cell-free therapeutic with potential safety and efficacy advantages over autologous cell therapies for the treatment of solid tumours. INOVIQ will now progress to in vivo studies to evaluate the efficacy of its CAR-NK-exosomes in animal models of TNBC, with successful completion of these initial preclinical studies enabling the company to advance the development of CAR-NK-exosome therapy to IND-enabling studies and further clinical development.

Based on the promising in vitro results, INOVIQ will progress to in vivo studies to evaluate the efficacy of its CAR-NK-exosomes in animal models of triple-negative breast cancer. Successful completion of these initial preclinical studies will enable the company to advance the development of CAR-NK-exosome therapy to IND-enabling studies and further clinical development.